Article
Identification and characterization of non-canonical azole antifungal resistance pathways in Aspergillus fumigatus.
mBio - 9 Sept 2026
Delbaje Endrews, Ribeiro Matheus Mertz, Bitencourt Ricardo de Oliveira Barbosa, Lagrou Katrien, Hubka Vit, Pontes Laís, Schreiber Angélica Zaninelli, Robbins Nicole, Cowen Leah E, Dos Reis Thaila Fernanda, Goldman Gustavo H
Abstract excerpt
Human fungal infections, especially those caused by Aspergillus fumigatus, pose a significant global health threat, particularly in immunocompromised individuals. Azole antifungals are the primary treatment for this pathogen; however, the prevalence of azole-resistant A. fumigatus strains is steadily increasing. Mutations in cyp51A, which encodes an enzyme involved in ergosterol biosynthesis and the molecular...
Read the complete abstract on PubMedTopics
- Aspergillus fumigatus
- Drug Resistance, Fungal
- Antifungal Agents
- Azoles
- Fungal Proteins
